Recruiting
Asthma and Primary Arterial Hypertension: an Inflammatory Link?
A low-intervention, prospective, experimental study will be conducted with the overall aim of assessing the inflammatory, functional and clinical differences between patients with asthma and those with asthma and hypertension, in order to improve our understanding of asthma and its comorbidities
ClinicalTrials.gov IDNCT07903805
PhaseNot Applicable
Enrollment74
SponsorIstituti Clinici Scientifici Maugeri SpA
Age18 Years – 85 Years
SexALL
Conditions studied
Asthma Bronchial
About this study
A low-intervention, prospective, experimental study will be conducted with the overall aim of assessing the inflammatory, functional and clinical differences between patients with asthma and those with asthma and hypertension, in order to improve our understanding of asthma and its comorbidities
Interventions
- Other: measurement of inflammatory markers — measurement of inflammatory markers
Primary outcomes
- Interleukin 4 (at baseline and after 4 years)
- Interleukin 5 (at baseline and after 4 years)
- Interleukin 13 (at baseline and after 4 years)
- FEV1 (at baseline and after 4 years)
Eligibility information
Inclusion Criteria:
* Age ≥18 and ≤85 years;
* Diagnosis of moderate/severe asthma according to current Global Initiative for Asthma (GINA) guidelines
* Diagnosis of moderate/severe asthma according to current GINA guidelines and primary arterial hypertension according to current European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines
* Patients able to collaborate in the required procedures;
* Signed informed consent.
Exclusion Criteria:
* History of asthma exacerbation requiring changing of pharmacological treatment in the previous month.
* Active smoking status or ex-smoker with Pack/Year major than 10;
* BMI major than 30 Kg/m2;
* Pregnancy;
* Diagnosis of concomitant Chronic Obstructive Pulmonary Disease (COPD); Obstructive Sleep Apnoea Syndrome (OSA); Clinically significant bronchiectasis; Allergic bronchopulmonary aspergillosis (ABPA); Atopic dermatitis;
* Diagnosis of concomitant Autoimmune Diseases; History of Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or (Hepatitis C Virus)HCV ;
* Active significant infection
* Malignancy, current or within the past 5 years. Suspected malignancy or undefined neoplasms;
* Cognitive impairment;
* History of clinically significant chronic heart diseases;
Study locations
- IRCSS ICS Maugeri Tradate, Tradate, Varese 21049 Italy
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-19.